You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The biotech will begin clinical trials of its lead drug candidates in ROS1-positive and ALK-positive non-small cell lung cancer in 2021 and 2022, respectively.
The researchers will compare saliva and plasma samples from 50 patients with non-small cell lung cancer to identify circulating tumor DNA in saliva.
A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.
The test will be used in the trial to improve understanding of molecular resistance mechanisms to Pfizer's Lorviqua and other ALK inhibitors.
OncoHost will use the funding to finance clinical trials, open a US location, and prepare to launch its proteomics platform called Prophet.
Zai Lab paid $25 million upfront for rights to develop and commercialize TPX-0022 in mainland China, Hong Kong, Macau, and Taiwan.
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
After the CANTATA trial failed, the company said it will reduce its workforce and direct resources to advancing the drug in KEAP1/NRF2-mutated NSCLC.
The company submitted data on amivantamab as a treatment for metastatic non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
Zai Lab will pay Cullinan $20 million upfront to license the drug in Greater China and could pay up to $211 million in future milestones and royalties.